212 related articles for article (PubMed ID: 19696677)
41. Emerging therapies in cystic fibrosis.
Anderson P
Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
[TBL] [Abstract][Full Text] [Related]
42. Emerging drugs for cystic fibrosis.
Amin R; Ratjen F
Expert Opin Emerg Drugs; 2014 Mar; 19(1):143-55. PubMed ID: 24479826
[TBL] [Abstract][Full Text] [Related]
43. The Evolution of Cystic Fibrosis Care.
Pittman JE; Ferkol TW
Chest; 2015 Aug; 148(2):533-542. PubMed ID: 25764168
[TBL] [Abstract][Full Text] [Related]
44. Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.
Torphy TJ; Allen J; Cantin AM; Konstan MW; Accurso FJ; Joseloff E; Ratjen FA; Chmiel JF;
Ann Am Thorac Soc; 2015 Sep; 12(9):1398-406. PubMed ID: 26146892
[TBL] [Abstract][Full Text] [Related]
45. Cystic fibrosis: a review of pulmonary and nutritional therapies.
Amin R; Ratjen F
Adv Pediatr; 2008; 55():99-121. PubMed ID: 19048729
[TBL] [Abstract][Full Text] [Related]
46. Progress towards next-generation therapeutics for cystic fibrosis.
O'Neil DA; Fraser-Pitt D
Future Med Chem; 2014 Jun; 6(9):1067-79. PubMed ID: 25068988
[TBL] [Abstract][Full Text] [Related]
47. New and emerging therapies for pulmonary complications of cystic fibrosis.
Tonelli MR; Aitken ML
Drugs; 2001; 61(10):1379-85. PubMed ID: 11558827
[TBL] [Abstract][Full Text] [Related]
48. Emerging treatments in cystic fibrosis.
Jones AM; Helm JM
Drugs; 2009 Oct; 69(14):1903-10. PubMed ID: 19747007
[TBL] [Abstract][Full Text] [Related]
49. Advances in cystic fibrosis therapies.
Rowe SM; Clancy JP
Curr Opin Pediatr; 2006 Dec; 18(6):604-13. PubMed ID: 17099358
[TBL] [Abstract][Full Text] [Related]
50. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
Jiang Q; Engelhardt JF
Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
[TBL] [Abstract][Full Text] [Related]
51. Adherence to therapies in cystic fibrosis: a targeted literature review.
Narayanan S; Mainz JG; Gala S; Tabori H; Grossoehme D
Expert Rev Respir Med; 2017 Feb; 11(2):129-145. PubMed ID: 28107795
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.
Chopra R; Paul L; Manickam R; Aronow WS; Maguire GP
Expert Opin Drug Saf; 2015 Mar; 14(3):401-11. PubMed ID: 25604518
[TBL] [Abstract][Full Text] [Related]
53. Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction.
Toprak D; Davis C; Rosenfeld M
Semin Respir Crit Care Med; 2019 Dec; 40(6):751-761. PubMed ID: 31659732
[TBL] [Abstract][Full Text] [Related]
54. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
Desch M
Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
[No Abstract] [Full Text] [Related]
55. Cystic Fibrosis: Emerging Understanding and Therapies.
Rey MM; Bonk MP; Hadjiliadis D
Annu Rev Med; 2019 Jan; 70():197-210. PubMed ID: 30312551
[TBL] [Abstract][Full Text] [Related]
56. New therapies for cystic fibrosis.
Simakajornboon N; Davis SH
J La State Med Soc; 1998 Dec; 150(12):629-37. PubMed ID: 9926704
[TBL] [Abstract][Full Text] [Related]
57. Cystic fibrosis 2019: Year in review.
Doull I
Paediatr Respir Rev; 2020 Sep; 35():95-98. PubMed ID: 32359945
[TBL] [Abstract][Full Text] [Related]
58. Treatment strategies for cystic fibrosis: what's in the pipeline?
Frerichs C; Smyth A
Expert Opin Pharmacother; 2009 May; 10(7):1191-202. PubMed ID: 19405793
[TBL] [Abstract][Full Text] [Related]
59. Identifying novel endpoints for cystic fibrosis clinical trials.
Sagel SD
Adv Pediatr; 2005; 52():115-27. PubMed ID: 16124338
[TBL] [Abstract][Full Text] [Related]
60. Update in cystic fibrosis 2013.
Jain M; Goss CH
Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
